International Assets Investment Management LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 27,868 shares of the biopharmaceutical company’s stock, valued at approximately $1,030,000.
Other institutional investors also recently modified their holdings of the company. EP Wealth Advisors LLC acquired a new position in Halozyme Therapeutics in the third quarter valued at $211,000. Pathstone Family Office LLC acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at about $219,000. Tocqueville Asset Management L.P. bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $225,000. Gallacher Capital Management LLC acquired a new stake in Halozyme Therapeutics during the third quarter worth approximately $235,000. Finally, Dark Forest Capital Management LP bought a new stake in Halozyme Therapeutics in the third quarter worth approximately $236,000. 97.79% of the stock is owned by institutional investors.
Insider Activity
In related news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $39.55, for a total transaction of $395,500.00. Following the transaction, the senior vice president now directly owns 156,558 shares in the company, valued at $6,191,868.90. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 30,000 shares of company stock worth $1,196,800 over the last quarter. Insiders own 2.70% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on Halozyme Therapeutics
Halozyme Therapeutics Price Performance
HALO stock opened at $38.71 on Tuesday. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64. The business has a 50-day simple moving average of $39.56 and a two-hundred day simple moving average of $37.77. The company has a market capitalization of $4.92 billion, a P/E ratio of 18.35, a price-to-earnings-growth ratio of 0.45 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 52-week low of $29.85 and a 52-week high of $45.00.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The company had revenue of $230.04 million for the quarter, compared to analysts’ expectations of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. Research analysts expect that Halozyme Therapeutics, Inc. will post 3.45 EPS for the current fiscal year.
Halozyme Therapeutics Profile
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Featured Articles
- Five stocks we like better than Halozyme Therapeutics
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Merger or Not, Albertson’s Companies is a Good Buy
- What Are Dividend Challengers?
- 3 Cheap Stocks That Shouldn’t Be So
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.